Loading...
The Need for SMN-Independent Treatments of Spinal Muscular Atrophy (SMA) to Complement SMN-Enhancing Drugs
Spinal Muscular Atrophy (SMA) is monogenic motoneuron disease caused by low levels of the Survival of Motoneuron protein (SMN). Recently, two different drugs were approved for the treatment of the disease. The antisense oligonucleotide Nusinersen/Spinraza® and the gene replacement therapy Onasemnoge...
Na minha lista:
| Udgivet i: | Front Neurol |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7009174/ https://ncbi.nlm.nih.gov/pubmed/32117013 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2020.00045 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|